Dr. Nathalie Johnson, M.D., FACS, Joins Gamma Medica’s Clinical Advisory Board

SALEM, N.H.--()--Gamma Medica, a leader in molecular breast imaging technology (MBI), announced today that Dr. Nathalie Johnson, M.D., FACS, of the Legacy Cancer Institute and the Legacy Breast Health Centers in Portland, Oregon has agreed to join the organizations’ clinical advisory board, currently comprised of distinguished clinicians and thought leaders with expertise in women’s health technologies and diagnostic imaging. Dr. Johnson and the board will provide strategic and clinical advice as Gamma Medica continues commercialization and enhancements of its LumaGEM® Molecular Breast Imaging system.

Dr. Johnson is a prominent surgical oncologist and medical director of the Legacy Breast Health Centers. She grew up in St. Thomas, U.S. Virgin Islands and earned her bachelor’s degree in radiation therapy technology at Howard University in Washington, D.C. and her medical degree at the Medical College of Virginia (VCU).

“Gamma Medica is committed to providing a more effective breast cancer detection option for women with dense breast tissue,” said Philip Croxford, president and CEO of Gamma Medica. “As a thought leader in the breast surgical space, we look forward to working with Dr. Johnson as a key contributor to our team of medical experts and leading clinical radiologists, ensuring our product offers benefits to patients, clinicians and the health care system overall.”

MBI is a groundbreaking technology that eliminates key shortcomings of traditional anatomical imaging technologies such as mammography and ultrasound by significantly improving early diagnosis of breast cancer in women with dense breast tissue. Detecting cancer in dense breast tissue is challenging, as both lesions and dense tissue appear white on a traditional mammogram.1 MBI is a functional imaging modality that highlights metabolic activity in breast tumors that a mammogram would not be able to read through dense tissue, thereby leading to earlier, specific diagnosis, improved outcomes and lowered costs.2,3 LumaGEM has also proven to reduce painful and costly biopsies by 50 percent.2

“As health care professionals we take care of others every day,” said Dr. Johnson. “Molecular Breast Imaging offers the opportunity to bring access to advanced breast imaging for patients in suburban areas and centers without the finances to support expensive breast MRI. I look forward to utilizing my experiences with MBI and expertise in breast care in collaboration with the board and Gamma Medica, which continues to develop and to integrate this important tool.”

About the Screening Challenge Posed by Dense Breast Tissue
Studies estimate that between 40 and 50 percent of women in the United States have dense breast tissue, which makes mammography less sensitive in detecting cancer.4 Women with dense breast tissue have a higher risk of breast cancer (four to five times greater than the general population), and it has been estimated that screening mammography misses approximately 70 percent of the cancers ultimately found in this population.

About Gamma Medica, Inc.
Gamma Medica, Inc. is a women’s health company focused on overcoming the limitations of anatomical imaging used by mammography and other screening modalities in the early detection of breast cancer. The company’s LumaGEM® MBI system is the first commercially available, FDA-approved, fully solid-state digital imaging system utilizing dual-head Digital Direct Conversion Gamma Imaging™ (DDCGI™) technology for molecular breast imaging. With over 90-percent sensitivity and specificity, LumaGEM MBI has been shown to significantly improve cancer detection in women with dense breast tissue with fewer false positives relative to anatomical imaging technologies, such as MRI and whole breast ultrasound. For more information visit, www.gammamedica.com.

1 Mayo Clinic. Tests and Procedures Mammogram. http://www.mayoclinic.org/tests-procedures/mammogram/in-depth/dense-breast-tissue/art-20123968?pg=2

2 Rhodes DJ, HruskaCB, ConnersAL, et al. JOURNAL CLUB: Molecular Breast Imaging at Reduced Radiation Dose for Supplemental Screening in Mammographically Dense Breasts. American Journal of Roentgenology. 2015;204(2):241-251.

3 Hruska CB, Conners AL, Jones KN, et al. Diagnostic Workup and Costs of a Single Supplemental Molecular Breast Imaging Screen of Mammographically Dense Breasts. American Journal of Roentgenology. 2015;204(6):1345-1353.

4 Kolb TM, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. Radiology. 2002;225(1):165–175.

Contacts

Racepoint Global
Tara Kadioglu, 617-624-3239
tkadioglu@racepointglobal.com

Contacts

Racepoint Global
Tara Kadioglu, 617-624-3239
tkadioglu@racepointglobal.com